TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25700754

Group type: EXPERIMENTAL
Intervention: Tryton Side Branch Stent
Number of subjects: 326

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 326
Study: 23649997

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with temozolomide (TMZ) - 200 mg/m² for 5 days post-surgery, followed by 75 mg/m² daily during radiotherapy, and 150-200 mg/m² for 5 days every 28 days after radiotherapy.
Number of subjects: 58

Group type: COMPARATOR
Intervention: Radiotherapy alone - involved-field radiotherapy in 2 Gy fractions daily for 6 weeks (total of 60 Gy).
Number of subjects: 58
Study: 20587052

Group type: EXPERIMENTAL
Intervention: Fructose 1, 6 diphosphate (FDP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 0
Study: 18398094

Group type: EXPERIMENTAL
Intervention: Six TAC cycles (n = 686)
Number of subjects: 1390

Group type: EXPERIMENTAL
Intervention: Eight TAC cycles (n = 704)
Number of subjects: 1390
Study: 16809799

Group type: EXPERIMENTAL
Intervention: Lanthanum chloride (LaCl3) intravenous infusion (120 microg elemental lanthanum over a 4-hour period)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chewable lanthanum carbonate (La2(CO3)3) tablets (1-g oral dose; 4 x 250 mg elemental lanthanum)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 24
Study: 14535906

Group type: EXPERIMENTAL
Intervention: LMA insertion by the lateral approach with cuff partially inflated (group LP)
Number of subjects: 62

Group type: COMPARATOR
Intervention: LMA insertion by the midline approach with cuff completely deflated (group MD)
Number of subjects: 62
Study: 11057850

Group type: EXPERIMENTAL
Intervention: Acenocoumarol (INR 2.0‐3.0)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Enoxaparin (4000 anti‐Xa units once a day)
Number of subjects: 100
Study: 9284854

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.20 mg/kg every 12 hours) + Furosemide (1 mg/kg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Indomethacin (0.20 mg/kg every 12 hours)
Number of subjects: 36
Study: 8300705

Group type: EXPERIMENTAL
Intervention: Tanner skin mesher with expansion ratios of 1.5:1 and 3:1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bioplasty skin mesher with expansion ratios of 2:1 and 4:1
Number of subjects: 20
Study: 3455968

Group type: EXPERIMENTAL
Intervention: 60 mg of AA per day for two weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: 0 mg (placebo) per day for four weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 600 mg per day for three weeks
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 0 mg per day for four weeks
Number of subjects: 11
Study: 29072472

Group type: EXPERIMENTAL
Intervention: Growing Pro-Social (GPS) Program
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 254
Study: 27022882

Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning (IPOC) immediately after thrombus aspiration (TA) followed by stenting of the IRA
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional percutaneous coronary intervention (PCI), including TA followed by stenting of the IRA
Number of subjects: 72
Study: 24018106

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-propofol
Number of subjects: 46

Group type: COMPARATOR
Intervention: Ketamine-propofol
Number of subjects: 46
Study: 22353456

Group type: EXPERIMENTAL
Intervention: 4% articaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: 3% mepivacaine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 4% articaine and 3% mepivacaine
Number of subjects: 50
Study: 20728687

Group type: EXPERIMENTAL
Intervention: GBG‐response cost
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GBG‐reinforcement
Number of subjects: 6
Study: 19064449

Group type: EXPERIMENTAL
Intervention: Parent education programs
Number of subjects: 58
Study: 15752096

Group type: EXPERIMENTAL
Intervention: Zinc tablets
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Chlorhexidine tablets and mouthwash
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Lyophilized lactic acid-forming bacteria
Number of subjects: 84

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 84
Study: 12677364

Group type: EXPERIMENTAL
Intervention: Cyclosporine-based immunosuppressive therapy
Number of subjects: 72
Study: 11971305

Group type: EXPERIMENTAL
Intervention: Continuing professional education programmes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomised control trial (RCT) methodology
Number of subjects: 0
Study: 8799424

Group type: EXPERIMENTAL
Intervention: RO‐11 at a daily s.c. dose of 2,500 anti‐FXa IU
Number of subjects: 100

Group type: COMPARATOR
Intervention: Calcium unfractionated heparin (UH) at a s.c. dose of 5,000 IU 12 hourly
Number of subjects: 100
Study: 1453197

Group type: EXPERIMENTAL
Intervention: Continuous therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intermittent therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline and change in scores for physical well-being (PWB), mood, pain, and QLI after the first three treatment cycles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QLI and PWB scores
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QL improvement
Number of subjects: 0
Study: 6606942

Group type: EXPERIMENTAL
Intervention: 1 mg of glucagon
Number of subjects: 133

Group type: COMPARATOR
Intervention: 1 ml of saline placebo
Number of subjects: 133
Study: 31006282

Group type: EXPERIMENTAL
Intervention: Hourly titrated oral misoprostol
Number of subjects: 150

Group type: COMPARATOR
Intervention: 2-hourly static oral misoprostol
Number of subjects: 150
Study: 29652078

Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 5380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5380
Study: 25847293

Group type: EXPERIMENTAL
Intervention: Repeated Mailings (RM): eight Forever Free RP booklets sent to participants over 12 months
Number of subjects: 3458

Group type: COMPARATOR
Intervention: Usual Care: standard intervention provided by the quitline, including brief counseling and nicotine replacement therapy
Number of subjects: 3458

Group type: EXPERIMENTAL
Intervention: Massed Mailings: all eight Forever Free RP booklets sent upon enrollment
Number of subjects: 3458
Study: 25458046

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Normal Saline
Number of subjects: 150
Study: 22378736

Group type: EXPERIMENTAL
Intervention: n-3 PUFA intake below the median
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: n-3 PUFA intake above the median
Number of subjects: 408
Study: 20349229

Group type: EXPERIMENTAL
Intervention: Calcium 1,000 mg for 1 week followed by Vitamin D3 1,000 i.u. daily for 7 weeks
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Vitamin D3 1,000 i.u. daily for 7 weeks followed by Calcium 1,000 mg for 1 week
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D together
Number of subjects: 22
Study: 18387078

Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 497

Group type: COMPARATOR
Intervention: Neutral Protamine Hagedorn (NPH) insulin
Number of subjects: 497
Study: 15777441

Group type: EXPERIMENTAL
Intervention: Low dose vaginal misoprostol 25 microg every 4 hours (maximum of six doses)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Dinoprostone vaginal gel 1‐2 mg 6 hourly (maximum of 3 mg in 24 hours)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Low dose vaginal misoprostol
Number of subjects: 268

Group type: COMPARATOR
Intervention: Dinoprostone vaginal gel
Number of subjects: 268
Study: 12139289

Group type: EXPERIMENTAL
Intervention: Frequent episodes of AF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infrequent episodes of AF
Number of subjects: 0
Study: 10459118

Group type: EXPERIMENTAL
Intervention: Nalmefene
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 7869560

Group type: EXPERIMENTAL
Intervention: Manual snow shoveling
Number of subjects: 10

Group type: COMPARATOR
Intervention: Automated snow removal
Number of subjects: 10
Study: 2691106

Group type: EXPERIMENTAL
Intervention: Compound five-Shen herbal drink (CFSHD) - Group I
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Compound five-Shen herbal drink (CFSHD) - Group II
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 600
Study: 608366

Group type: EXPERIMENTAL
Intervention: Methylphenidate (Ritalin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31284323

Group type: EXPERIMENTAL
Intervention: PCR TKA
Number of subjects: 120

Group type: COMPARATOR
Intervention: PS TKA
Number of subjects: 120
Study: 30844425

Group type: EXPERIMENTAL
Intervention: LPP (Lolium perenne peptide)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 28440812

Group type: EXPERIMENTAL
Intervention: Baclofen (30mg per day)
Number of subjects: 34
Study: 23903088

Group type: EXPERIMENTAL
Intervention: Botulinum toxin (100 U) injected into the pectoralis muscle
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo injected into the contralateral side
Number of subjects: 23
Study: 23670576

Group type: EXPERIMENTAL
Intervention: Endostar (7.5 mg/m²) plus dacarbazine (250 mg/m²)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo plus dacarbazine (250 mg/m²)
Number of subjects: 110
Study: 21031343

Group type: EXPERIMENTAL
Intervention: Combination therapy with fixed dose of 4 mg rosiglitazone plus 500 mg metformin (RSG+MET group, n = 70)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Half-maximum dose of metformin monotherapy (MET group, n = 70)
Number of subjects: 140
Study: 19558782

Group type: EXPERIMENTAL
Intervention: Anterograde intracoronary artery (ICA) delivery of 100 million BMMNC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Retrograde intracoronary vein (ICV) delivery of 100 million BMMNC
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 16822278

Group type: EXPERIMENTAL
Intervention: Zolpidem with voriconazole pretreatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Zolpidem without voriconazole pretreatment
Number of subjects: 10
Study: 11040881

Group type: EXPERIMENTAL
Intervention: Breast-feeding
Number of subjects: 23303
Study: 8879373

Group type: EXPERIMENTAL
Intervention: Chemotherapy (sequential 5‐fluorouracil/leucovorin combined with etoposide or FLv for elderly/poor performance patients)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 90
Study: 2049700

Group type: EXPERIMENTAL
Intervention: Insulin use among diagnosed diabetics
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prevalence rate by gender
Number of subjects: 100
Study: 6362699

Group type: EXPERIMENTAL
Intervention: Brotizolam 0.25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brotizolam 0.5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitrazepam 5.0 mg
Number of subjects: 0
Study: 31172740

Group type: EXPERIMENTAL
Intervention: Three-qubit randomized benchmarking (RB) with all-to-all gate connectivity
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Three-qubit randomized benchmarking (RB) with linear gate connectivity
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Three-qubit randomized benchmarking (RB) with coherent errors introduced
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Simultaneous one- and two-qubit RB
Number of subjects: 3
Study: 29275334

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 26443019

Group type: EXPERIMENTAL
Intervention: 30 mg zinc tablets daily for 12 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo tablets daily for 12 months
Number of subjects: 40
Study: 24698202

Group type: EXPERIMENTAL
Intervention: Radiofrequency volumetric thermal ablation (RFVTA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopic myomectomy (LM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RFVTA
Number of subjects: 0

Group type: COMPARATOR
Intervention: LM
Number of subjects: 0
Study: 22152099

Group type: EXPERIMENTAL
Intervention: High-density negative ion (HDNI) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20546266

Group type: EXPERIMENTAL
Intervention: Medication possession ratio (MPR)
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Morisky Medication-taking Scale
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Medication-taking item of the Summary of Diabetes Self-Care Activities (SDSCA)
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Self-report adherence measures
Number of subjects: 526
Study: 18056491

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (20 digits)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo injection (15 digits)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nondiabetic group (29 digits)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diabetic corticosteroid group (19 digits)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diabetic placebo group (15 digits)
Number of subjects: 30
Study: 16211735

Group type: EXPERIMENTAL
Intervention: Etomidate (0.2 mg kg[-1])
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol (2 mg kg[-1])
Number of subjects: 0
Study: 11945098

Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride 1200 mg/day
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 10096369

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 3040

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3040
Study: 8773063

Group type: EXPERIMENTAL
Intervention: Mefenamic acid 6.5 mg/kg
Number of subjects: 78

Group type: COMPARATOR
Intervention: Paracetamol 10 mg/kg
Number of subjects: 78

Group type: COMPARATOR
Intervention: Ibuprofen 7 mg/kg
Number of subjects: 78
Study: 1689173

Group type: EXPERIMENTAL
Intervention: Terazosin (10 mg/day)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 31639150

Group type: EXPERIMENTAL
Intervention: High-efficiency on-line hemodiafiltration (HDF)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Conventional low-flux hemodialysis (HD)
Number of subjects: 113
Study: 28505292

Group type: EXPERIMENTAL
Intervention: Real Auricular Point Acupressure (APA)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham Auricular Point Acupressure (APA)
Number of subjects: 29
Study: 26549134

Group type: EXPERIMENTAL
Intervention: Bilateral infraorbital and infratrochlear nerve blocks with 10 mL of 0.25% levobupivacaine (Group LB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (isotonic saline)
Number of subjects: 40
Study: 24430534

Group type: EXPERIMENTAL
Intervention: rilpivirine 25 mg once daily
Number of subjects: 690

Group type: COMPARATOR
Intervention: efavirenz 600 mg once daily
Number of subjects: 690
Study: 22341989

Group type: EXPERIMENTAL
Intervention: Single-session group
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Dual-session group
Number of subjects: 48
Study: 21775113

Group type: EXPERIMENTAL
Intervention: Prescription omega-3-acid ethyl esters (POM3)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Corn oil
Number of subjects: 19
Study: 18040542

Group type: EXPERIMENTAL
Intervention: Clinical holistic medicine (CHM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard psychiatric treatment (TAU)
Number of subjects: 0
Study: 16221265

Group type: COMPARATOR
Intervention: One extrastimulus
Number of subjects: 121

Group type: COMPARATOR
Intervention: Two extrastimuli
Number of subjects: 121

Group type: COMPARATOR
Intervention: Follow-up
Number of subjects: 121
Study: 11897585

Group type: EXPERIMENTAL
Intervention: 500 mg of artemisinin daily for 5 days (group A; n = 40)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Artemisinin at a dose of 100 mg per day for 2 days, increased to 250 mg per day for 2 consecutive days, and 500 mg on the fifth day (group B; n = 37)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Group A (500 mg daily for 5 days)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Group B (escalating doses of artemisinin)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both groups on day 5
Number of subjects: 77
Study: 10631689

Group type: EXPERIMENTAL
Intervention: High-dose (dose-intensive) therapy for breast cancer
Number of subjects: 0
Study: 7498206

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 1702552

Group type: EXPERIMENTAL
Intervention: Dextran + Acetylsalicylic Acid
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Low dose of Heparin (Kakkar protocol)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Haemodilution
Number of subjects: 151
Study: 7009254

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31534374

Group type: EXPERIMENTAL
Intervention: Polyphenol compound supplementation (Vertigoval) for 60 days
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 258
Study: 28675566

Group type: EXPERIMENTAL
Intervention: Glutamine-fiber-oligosaccharide treatment group (n=11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Glutamine F treatment group (n=11)
Number of subjects: 22
Study: 25851721

Group type: EXPERIMENTAL
Intervention: Comprehensive medical education program (1h/day for 5 days) and specific drug therapy
Number of subjects: 76

Group type: COMPARATOR
Intervention: Only drug therapy
Number of subjects: 76
Study: 23453362

Group type: EXPERIMENTAL
Intervention: Initial serum magnesium concentration >1.6 mg/dL
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Initial serum magnesium concentration (median [IQ range])
Number of subjects: 156
Study: 21084184

Group type: COMPARATOR
Intervention: Preoperative chemotherapy (CT) with cisplatin (80 mg/m(2)) and infusional 5 fluorouracil (1000 mg/m(2)/d) on days 1 and 21
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation therapy (CRT) with cisplatin (80 mg/m(2)), infusional 5 fluorouracil (800 mg/m(2)/d) starting on day 21, and radiation therapy (35 Gy in 15 fractions over 3 weeks)
Number of subjects: 75
Study: 19833052

Group type: EXPERIMENTAL
Intervention: Prednisolone (50 mg per day)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Aciclovir (2000 mg per day)
Number of subjects: 496

Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 496

Group type: EXPERIMENTAL
Intervention: Aciclovir and Prednisolone
Number of subjects: 496

Group type: COMPARATOR
Intervention: Placebo and Placebo
Number of subjects: 496
Study: 17261397

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/day)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/day)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (no statin treatment)
Number of subjects: 73
Study: 15371775

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of 0.25% bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single dose caudal injection of 0.25% bupivacaine
Number of subjects: 0
Study: 11345631

Group type: EXPERIMENTAL
Intervention: MR total spine imaging
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (patients without scoliosis)
Number of subjects: 50
Study: 9510574

Group type: COMPARATOR
Intervention: Spiral CT
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Incremental CT
Number of subjects: 46
Study: 7732541

Group type: EXPERIMENTAL
Intervention: Sodium fluoride tablets administered since age 2
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluorine varnish and sealing of fissures with vitacryl
Number of subjects: 12
Study: 3133708

Group type: EXPERIMENTAL
Intervention: Trazodone (150 mg daily)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Mianserin (30 mg for 7 days, then 60 mg daily)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Dothiepin (75 mg for 1 week, then 150 mg daily)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Amitriptyline (75 mg for 1 week, then 100 mg daily)
Number of subjects: 227
Study: 29903422

Group type: EXPERIMENTAL
Intervention: Daily bladder irrigation with 450 cc sterile normal saline, in 3 150‐mL doses, for 3 consecutive days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no bladder irrigation)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Daily bladder irrigation with normal saline
Number of subjects: 100
Study: 27932360

Group type: EXPERIMENTAL
Intervention: High-Intensity Functional Exercise (HIFE) group
Number of subjects: 468

Group type: COMPARATOR
Intervention: Individual physiotherapy sessions
Number of subjects: 468
Study: 25483780

Group type: EXPERIMENTAL
Intervention: Peer-delivered telephone support
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Nurse-delivered telephone counselling
Number of subjects: 189

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 189
Study: 24636287

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) 0.5 mg/day
Number of subjects: 232
Study: 21790238

Group type: EXPERIMENTAL
Intervention: Ubenimex capsule (30mg daily for 8 weeks)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no ubenimex)
Number of subjects: 63
Study: 19023743

Group type: EXPERIMENTAL
Intervention: Assessment of judgment ability using various techniques
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Top-ranked instruments for assessing judgment
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Confidence in assessing judgment skills
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Perceived need for improved measures
Number of subjects: 290
Study: 16582124

Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 14742994

Group type: EXPERIMENTAL
Intervention: Daclizumab treatment in combination with tacrolimus and mycophenolate mofetil
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Calculated fractional excretion of sIL‐2Rα
Number of subjects: 46